- TRADE NAME: Ilumya (Merck Sharpe & Dohme)
- INDICATIONS: Moderate-to-severe plaque psoriasis
- CLASS: Interleukin-17 (IL-17) antagonist / interleukin-17 inhibitor, Interleukin-23 inhibitor, Monoclonal antibody
- HALF-LIFE: 23 days
- FDA APPROVAL DATE: 03/20/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Live vaccines - PREGNANCY: Insufficient data to inform drug-associated risk
- See adverse reactions attributed to class:
Interleukin-17 (IL-17) antagonist / interleukin-17 inhibitor
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of tildrakizumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/20/2025
